Coagulation Index to Distinguish Severe Preeclampsia from Normal Pregnancy

ABSTRACT

The purpose of this study was to establish a new coagulation index to distinguish severe preeclampsia from normal pregnancy using optimal coagulation parameters. The difference between platelet counts in early gestation and before delivery (ΔPlt = [platelet counts before delivery] - [platelet counts in early gestation]) was calculated as an index of changes in platelet counts. Antithrombin (AT) activity, thrombin-antithrombin (TAT) complex, fibrin degradation products (FDP) D-dimer, and ΔPlt were investigated in 72 cases of normal pregnant women in the third trimester of pregnancy and 56 cases of severe preeclampsia. The new coagulation index was calculated using multivariate logistic regression analysis. As a result, in a case using four parameters, the following formula was obtained: Y = (-0.019 × AT activity) + (0.067 × TAT) + (0.067 × D-dimer) + (-0.064 × ΔPlt) + 0.706. According to this formula, coagulation indices in normal pregnant women and in patients with severe preeclampsia were -0.77 ± 0.51 and 1.41 ± 1.56, respectively (p < 0.0001). Among patients with severe preeclampsia, coagulation and fibrinolysis disorders before delivery were typical in patients terminated by cesarean section (coagulation index = 1.62 ± 1.66) compared with those with successful vaginal delivery (coagulation index = 0.52 ± 0.34) (p < 0.05). These facts suggest that an excessive hypercoagulable state is associated with the termination of pregnancy resulting from the aggravation of preeclampsia. From the viewpoint of coagulation and fibrinolysis disorders, the predictive value in order to decide the optimal time for the termination of pregnancy could be recommended when the coagulation index exceeded 1.20.

KEYWORD

Preeclampsia - coagulation index - platelet counts - FDP D-dimer - thrombin-antithrombin (TAT) complex

REFERENCES

• 1 Kobayashi T, Tokunaga N, Sugimura M, Kanayama N, Terao T. Vasospasms are characteristic in cases with eclampsia/ preeclampsia and HELLP syndrome: proposal of angiospastic syndrome of pregnancy.  Semin Thromb Hemost . 2001;  27 131-135
• 2 Kobayashi T, Terao T. Preeclampsia as chronic disseminated intravascular coagulation.  Gynecol Obstet Invest . 1987;  24 170-178
• 3 Kelton J G, Hunter D JS, Neame P B. A platelet function defect in pre-eclampsia.  Obstet Gynecol . 1985;  65 107-109
• 4 Kobayashi T, Tokunaga N, Sugimura M. Coagulation/ fibrinolysis disorder in patients with severe preeclampsia.  Semin Thromb Hemost . 1999;  25 451-454
• 5 Kobayashi T, Tokunaga N, Sugimura M, Kanayama N, Terao T. Predictive values of coagulation/fibrinolysis parameters for the termination of pregnancy complicated by severe preeclampsia.  Semin Thromb Hemost . 2001;  27 137-141
• 6 Chen J, Ishii M, Wang L, Ishii K, Coughlin S R. Thrombin receptor activation.  J Biol Chem . 1994;  269 16041-16045
• 7 Rabiet M J, Plantier J L, Dejana E. Thrombin-induced endothelial cell dysfunction.  Br Med Bull . 1994;  50 936-945
• 8 Khatun S, Kanayama N, Belayet H. The impact of vasoactive peptides on nitric oxide production in cultured sympathetic neurons.  Neuroscience . 1999;  93 605-609
• 9 Khatun S, Kanayama N, Belayet H. Increased concentrations of plasma neuropeptide-Y in patients with eclampsia and preeclampsia.  Am J Obstet Gynecol . 2000;  182 896-900
• 10 Page N M, Woods R J, Gardiner S M. Excessive placental secretion of neurokinin B during the third trimester causes pre-eclampsia.  Nature . 2000;  405 797-800
• 11 Terao T, Kobayashi T, Imai N, Oda H, Karasawa T. Pathological state of the coagulatory and fibrinolytic system in preeclampsia and the possibility of its treatment with AT-III concentrate.  Asia-Oceania J Obstet Gynecol . 1989;  15 25-32
• 12 Maki M, Kobayashi T, Terao T. Antithrombin therapy for severe preeclampsia: Results of a double blind, randomized, placebo-controlled trial.  Thromb Haemost . 2000;  84 583-590
• 13 Terao T, Maki M, Ikenoue T. The relationship between clinical signs and hypercoagulable state in toxemia of pregnancy.  Gynecol Obstet Invest . 1991;  31 74-85